Cardiac events in the setting of ofatumumab treatment: An association or A Co-incidence?

Despite its rarity, concerns about cardiac complications could be linked to ofatumumab in line with its cardiac risks in non-MS treatments. Here, we provide a first-time report of two instances of acute myocardial events in women under 50 temporally associated with ofatumumab for the treatment of multiple sclerosis (MS). Both patients were also on stimulant medications, suggesting that clinicians should take caution when prescribing anti-CD20 agents to patients with cardiovascular risk factors or concomitant use of stimulants. Further research is needed to confirm and quantify the association between anti-CD20 agents in use in patients with cardiovascular risk factors on concomitant use of stimulants.